Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGTX Stock Forecast 2026-2027
$10.53
Current Price
$974.63M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MGTX Price Targets
+374.8%
To High Target of $50.00
+137.4%
To Median Target of $25.00
+70.9%
To Low Target of $18.00
MGTX Price Momentum
-6.7%
1 Week Change
+46.3%
1 Month Change
+86.4%
1 Year Change
+32.5%
Year-to-Date Change
-11.1%
From 52W High of $11.85
+131.4%
From 52W Low of $4.55
📊 TOP ANALYST CALLS
Did MGTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MeiraGTx is one of their latest high-conviction picks.
Latest MGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, MGTX has a bullish consensus with a median price target of $25.00 (ranging from $18.00 to $50.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $10.53, the median forecast implies a 137.4% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Gavin Clark-Gartner at Evercore ISI Group, suggesting a 70.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGTX Analyst Ratings
8
Buy
0
Hold
0
Sell
MGTX Price Target Range
Low
$18.00
Average
$25.00
High
$50.00
Current: $10.53
Latest MGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | RBC Capital | Lisa Walter | Outperform | Maintains | $24.00 |
| Apr 1, 2026 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $18.00 |
| Mar 27, 2026 | B of A Securities | Geoff Meacham | Buy | Maintains | $16.00 |
| Mar 27, 2026 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $26.00 |
| Mar 27, 2026 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Nov 24, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Initiates | $20.00 |
| Nov 14, 2025 | RBC Capital | Lisa Walter | Outperform | Maintains | $16.00 |
| Nov 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Nov 11, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Nov 11, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $30.00 |
| Oct 21, 2025 | Raymond James | Christopher Raymond | Strong Buy | Initiates | $29.00 |
| Aug 15, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| May 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Mar 17, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $13.00 |
| Feb 24, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Nov 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Nov 14, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
| Aug 13, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $9.00 |
| Jul 31, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Mar 15, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $11.00 |
MeiraGTx Holdings plc (MGTX) Competitors
The following stocks are similar to MeiraGTx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MeiraGTx Holdings plc (MGTX) Financial Data
MeiraGTx Holdings plc has a market capitalization of $974.63M with a P/E ratio of -7.4x. The company generates $81.39M in trailing twelve-month revenue with a -140.3% profit margin.
Revenue growth is +252.3% quarter-over-quarter, while maintaining an operating margin of +35.1% and return on equity of -368.2%.
Valuation Metrics
Market Cap
$974.63M
Enterprise Value
$846.99M
P/E Ratio
-7.4x
PEG Ratio
-4.8x
Price/Sales
11.5x
Growth & Margins
Revenue Growth (YoY)
+252.3%
Gross Margin
+99.4%
Operating Margin
+35.1%
Net Margin
-140.3%
EPS Growth
+252.3%
Financial Health
Cash/Price Ratio
+7.7%
Current Ratio
0.7x
Debt/Equity
-15.3x
ROE
-368.2%
ROA
-25.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MeiraGTx Holdings plc (MGTX) Business Model
About MeiraGTx Holdings plc
What They Do
Develops gene therapies for serious diseases.
Business Model
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company that develops innovative treatments targeting genetic disorders, including ocular diseases and neurodegenerative conditions. The company generates revenue through strategic partnerships and collaborations in manufacturing and research, leveraging its proprietary technology platforms to create long-lasting therapeutic solutions.
Additional Information
The company is positioned within the biotechnology and pharmaceuticals sectors, attracting significant attention for its potential contributions to personalized medicine. With a strong scientific foundation, MeiraGTx aims to address unmet medical needs, impacting not only patients with genetic disorders but also expanding therapeutic options in various medical fields.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
400
CEO
Dr. Alexandria Forbes Ph.D.
Country
United States
IPO Year
2018
Website
www.meiragtx.comMeiraGTx Holdings plc (MGTX) Latest News & Analysis
Latest News
Quick Summary
MeiraGTx Holdings has signed an asset purchase agreement with Johnson & Johnson to acquire bota-vec, a treatment for X-linked retinitis pigmentosa (XLRP).
Why It Matters
MeiraGTx's acquisition of bota-vec from J&J enhances its pipeline in genetic therapies, potentially boosting growth and market position in the lucrative ophthalmology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings plc (MGTX) presented three-year Phase I data on AAV-hAQP1 targeting radiation-induced xerostomia, highlighting potential commercial opportunities.
Why It Matters
The discussion of Phase I data for AAV-hAQP1 signals potential advancements in treating radiation-induced xerostomia, highlighting MGTX's growth prospects and market opportunities.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings announced positive three-year results from its Phase 1 AQUAx study of AAV-hAQP1 for treating grade 2/3 late radiation-induced xerostomia.
Why It Matters
Positive three-year data from MeiraGTx's Phase 1 study indicates potential for a new treatment in a niche market, enhancing the company's growth prospects and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings (Nasdaq: MGTX) has priced an underwritten offering of 11.1 million shares at $9.00 each, aiming to raise approximately $100 million before expenses.
Why It Matters
MeiraGTx's $100 million share offering indicates a move to raise capital, potentially impacting stock dilution and investor sentiment regarding future growth and funding needs.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings will present 3-year data from its Phase 1 AQUAx Clinical Study on April 16, 2026, focusing on the treatment of radiation-induced xerostomia.
Why It Matters
The presentation of 3-year data from the AQUAx Clinical Study may indicate progress in treatment efficacy, influencing investor confidence and stock performance for MeiraGTx Holdings.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MeiraGTx: Turning Dry Mouth Into Liquid Gold
5 days ago
Quick Summary
MeiraGTx is set for a key Phase 1 data readout for AAV-hAQP1 in xerostomia. The stock reached 52-week highs, with projected peak sales of ~$1.2B and a risk-adjusted NPV of $979.8M.
Why It Matters
MeiraGTx's upcoming Phase 1 data readout could significantly impact its valuation, with potential for high sales and reduced investment risk, influencing stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About MGTX Stock
What is MeiraGTx Holdings plc's (MGTX) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, MeiraGTx Holdings plc (MGTX) has a median price target of $25.00. The highest price target is $50.00 and the lowest is $18.00.
Is MGTX stock a good investment in 2026?
According to current analyst ratings, MGTX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGTX stock?
Wall Street analysts predict MGTX stock could reach $25.00 in the next 12 months. This represents a 137.4% increase from the current price of $10.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MeiraGTx Holdings plc's business model?
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company that develops innovative treatments targeting genetic disorders, including ocular diseases and neurodegenerative conditions. The company generates revenue through strategic partnerships and collaborations in manufacturing and research, leveraging its proprietary technology platforms to create long-lasting therapeutic solutions.
What is the highest forecasted price for MGTX MeiraGTx Holdings plc?
The highest price target for MGTX is $50.00 from at , which represents a 374.8% increase from the current price of $10.53.
What is the lowest forecasted price for MGTX MeiraGTx Holdings plc?
The lowest price target for MGTX is $18.00 from Gavin Clark-Gartner at Evercore ISI Group, which represents a 70.9% increase from the current price of $10.53.
What is the overall MGTX consensus from analysts for MeiraGTx Holdings plc?
The overall analyst consensus for MGTX is bullish. Out of 11 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are MGTX stock price projections?
Stock price projections, including those for MeiraGTx Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 7:24 AM UTC